QuidelOrtho
QuidelOrtho develops and manufactures diagnostic tests - from rapid antigen and lateral-flow assays to molecular PCR - used across home, clinical laboratory, point-of-care and transfusion medicine settings worldwide.
QuidelOrtho is a pure-play diagnostics company formed by the combination of Quidel Corporation and Ortho Clinical Diagnostics. It develops and manufactures technologies intended to improve the performance of diagnostic testing. Its portfolio spans immunoassay, molecular testing, lateral-flow assays, rapid antigen diagnostics, PCR assays, point-of-care diagnostics and transfusion medicine testing. Tests detect conditions ranging from HIV and hepatitis C to influenza, strep and COVID-19.
The company operates across the healthcare continuum, from home to hospital and lab to clinic, with a global footprint in point-of-care settings, clinical laboratories and transfusion medicine. Its products include some notable firsts in the field: among the earliest lateral-flow pregnancy test strips, the first FDA-approved rapid antigen diagnostic test for influenza, and one of the earliest molecular PCR assays for SARS-CoV-2.
QuidelOrtho draws on more than 120 years of collective experience and innovation in diagnostics. Following the merger, the company describes a shared, mission-driven culture focused on developing and manufacturing innovative technologies that raise the performance of diagnostic testing and on providing health information when and where it is needed.